Outcome at Two Years after a Response-Adapted Approach with Azacitidine and Intensive Chemotherapy in Patients > 60 Years with Newly Diagnosed AML Treated within the DRKS00004519 Trial of the East German Study Group (OSHO)

• Published in: Blood 2018-11, Vol.132 (Supplement 1), p.83-83
• Main Authors: Jaekel, Nadia, Hubert, Karolin, Hänel, Mathias, Maschmeyer, Georg, Herbst, Regina, Schulze, Susann, Wang, Song-Yau, Kahl, Christoph, Wass, Maxi, Sayer, Herbert G., Brosteanu, Oana, Niederwieser, Dietger, Al-Ali, Haifa Kathrin
• Format: Article
• Language: English
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2018-99-115790

The heterogeneity of AML requires a personalized treatment strategy to achieve a high initial response and translate this response into long-term survival. Based on a possible synergistic effect of azacitidine (AZA) and cytarabine (ARA-C) when AZA is given first through the induction of deoxycytidine kinase by AZA which phosphorylates ARA-C to its active compound, ara-CTP, priming with AZA was integrated with intensive chemotherapy (IC) in a response-based sequential approach in the multicenter RAS-AZIC (DRKS00004519) study for patients (pts) >60 years (y). The safety, the remission rate of 64%, and a low TRM of 10% up to day (d) 90 were previously reported (Jaekel et al, ASH 2017). The final results of outcome at two years are presented. Patients and methods: Pts >60 y with newly diagnosed AML (de novo, secondary, and therapy related) were included (n=109). All received priming with AZA (75 mg/m2/day s.c) for 7 days. Irrespective of baseline bone marrow (BM) blasts, pts with d15 blasts ≥45% received IC (Mitoxantrone 10 mg/m2/day d1-3 and ARA-C 1g/m2/BID d1,3,5,7). If the count was